TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06943755: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Sponsor: Exelixis · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 440 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,340,028

Rescue Site Savings

+$2,874,564

Unlock Full NCT06943755 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06943755 Rescue Dossier →